文献速递消化道肿瘤放疗姑息放疗与转移瘤

盆腔骨剂量体积参数对I-III期直肠癌放疗骨髓抑制的影响

The Influence of Pelvic Bone Dose-volume Parameters on Bone Marrow Suppression During Radiation Therapy in Patients With Stage I to III Rectal Cancer Based on Real-world Data.
PubMed 文献 · Adv Radiat Oncol · 2024-10-24

基于单中心2016年1月至2022年9月连续纳入的130例I-III期直肠癌患者回顾性数据,评估盆腔骨剂量体积参数与新辅助或根治性放疗期间骨髓抑制的关系。多因素分析显示性别、IBM-Dmean、IBM-V15和IBM-V40与2级以上白细胞减少显著相关,联合预测AUC为0.834。含奥沙利铂同步化疗方案与2级以上血小板减少相关(P=0.054)。

要点

  • 女性、较高的IBM-Dmean、IBM-V15和IBM-V40与2级以上白细胞减少显著相关,联合预测AUC为0.834。
  • IBM-Dmean最佳截断值2692.75 cGy,IBM-V15为86.65%,IBM-V40为20.75%。
  • 含奥沙利铂同步化疗方案者更易发生2级以上血小板减少(P=0.054),预测AUC为0.678。

核心结论

  • 在接受新辅助或根治性放疗的I-III期直肠癌患者中,女性且IBM-Dmean、IBM-V15和IBM-V40较高的患者更易发生2级以上白细胞减少。
  • 含奥沙利铂同步化疗方案被识别为增加2级以上血小板减少发生率的潜在因素。

研究设计与样本

  • 本研究为单中心回顾性研究,数据来自电子病历回顾。
  • 2016年1月至2022年9月连续纳入接受新辅助放疗或根治性放疗的I-III期直肠癌患者,共130例具有完整临床资料。
  • 收集放疗期间完整基线外周血计数和血液学毒性数据,以及3个盆腔骨髓亚位点(髂骨骨髓IBM、腰骶骨骨髓、下骨盆骨髓)的剂量体积参数。
  • 主要终点为2级以上血液学毒性(HT2+),包括白细胞减少、中性粒细胞减少、贫血、血小板减少和总血液学毒性。
  • 采用逻辑回归分析HT2+与剂量学参数及临床病理特征的关联,并用受试者工作特征曲线及曲线下面积(AUC)验证预测效能。

主要发现

  • 共130例I-III期直肠癌患者纳入分析,新辅助放疗和根治性放疗期间57例(43.8%)发生HT2+。
  • 多因素分析显示性别、IBM-Dmean、IBM-V15和IBM-V40与2级以上白细胞减少显著相关(P < .05)。
  • 性别联合IBM-Dmean、IBM-V15和IBM-V40预测2级以上白细胞减少的AUC为0.834。
  • 预测2级以上白细胞减少的最佳截断值为IBM-Dmean = 2692.75 cGy、IBM-V15 = 86.65%、IBM-V40 = 20.75%。
  • 接受含奥沙利铂同步化疗方案者更易发生2级以上血小板减少(P = .054),同步化疗方案预测2级以上血小板减少的AUC为0.678。

关键数值与推荐

  • 2级以上白细胞减少的最佳截断值:IBM-Dmean = 2692.75 cGy、IBM-V15 = 86.65%、IBM-V40 = 20.75%。
  • 性别联合IBM-Dmean、IBM-V15和IBM-V40预测2级以上白细胞减少的AUC为0.834。
  • 同步化疗方案预测2级以上血小板减少的AUC为0.678。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为单中心回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the effect of pelvic bone dose-volume parameters on bone marrow suppression during radiation therapy (RT) in patients with rectal cancer stage I to III disease receiving either neoadjuvant radiation therapy (neo-RT) or curative-intent radiation therapy (cur-RT). METHODS AND MATERIALS: This was a retrospective study with data mined from an electronic medical record review at a single institution. Between January 2016 and September 2022, patients with rectal cancer who consecutively received neo-RT or cur-RT in our department were included. The data collected included complete baseline peripheral blood counts and hematologic toxicity (HT) data collected during RT. The radiation dose-volume parameters of 3 pelvic bone marrow subsites (iliac bone marrow [IBM], lumbosacral bone marrow, and lower pelvis bone marrow) were collected. The primary endpoint was grade ≥ 2 HT (HT2+), including leukopenia, neutropenia, anemia, thrombocytopenia, and total HTs. Logistic regression was employed to analyze the associations of HT2+ with dosimetric parameters and clinicopathologic characteristics. Receiver operating characteristic curves and the area under the curve (AUC) were generated to verify the prediction efficacy of the pelvic bone dose-volume parameters combined with clinicopathologic indices. RESULTS: A total of 130 patients with stage I to III rectal cancer with complete clinical data were included. During neo-RT and cur-RT, 57 (43.8%) of these patients experienced HT2+. Multivariate analysis revealed that gender, the IBM-Dmean, the IBM-V15, and the IBM-V40 were significantly associated with grade 2+ leukopenia (P < .05), and the AUC of gender combined with the IBM-Dmean, the IBM-V15, and the IBM-V40 in predicting grade 2+ leukopenia was 0.834. The optimal cutoff values were an IBM-Dmean = 2692.75 cGy, an IBM-V15 = 86.65%, and an IBM-V40 = 20.75%. Patients who received oxaliplatin-containing concurrent chemotherapy (ChT) regimens were more likely to experience grade 2+ thrombocytopenia (P = .054). The AUC of concurrent ChT regimens in predicting grade 2+ thrombocytopenia was 0.678. Female gender was significantly associated with grade 2+ anemia and total HT2+ status. CONCLUSIONS: Among patients with rectal cancer stage I to III disease who received neo-RT or cur-RT, female patients with higher IBM-Dmean, IBM-V15, and IBM-V40 were more likely to experience grade 2+ leukopenia, and oxaliplatin-containing concurrent ChT regimens were identified as a potential factor for increasing the incidence of grade 2+ thrombocytopenia.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Huang B, Lv J, Xiong J, et al. The Influence of Pelvic Bone Dose-volume Parameters on Bone Marrow Suppression During Radiation Therapy in Patients With Stage I to III Rectal Cancer Based on Real-world Data. Adv Radiat Oncol. 2024. PMID: 39655153. doi:10.1016/j.adro.2024.101662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。